Showing 5031-5040 of 9575 results for "".
- Can Phages Help Treat AD?https://practicaldermatology.com/news/can-phages-help-treat-adp/2462033/Bacteriophages or bacteria eaters may be a new therapy option for people with atopic dermatitis (AD), according to a study in Science Advances. A MedUni Vienna team has investigated t
- FDA Approves Merz Aesthetics’ Belotero Balance (+) for Infraorbital Hollowshttps://practicaldermatology.com/news/fda-approves-merz-aesthetics-belotero-balance-for-infraorbital-hollows/2462028/The U.S. Food and Drug Administration (FDA) approved Merz Aesthetics’ Belotero Balance (+) for improvement of the infraorbital hollow (IOH) in adults over the age of 21. This approval stems from positive pivotal study results demonstrating the efficacy and safety o
- DEF, SDPA Call Attention to Heart Health for World Heart Dayhttps://practicaldermatology.com/news/def-sdpa-call-attention-to-heart-health-for-world-heart-day/2462027/The Dermatology Education Foundation (DEF) and the Society of Dermatology Physician Assistants (SDPA) are calling on NPs and PAs in dermatology to take charge of their own health and support peers in recognition of World Heart Day on September 29, 2023. “As nurse practitioner
- Abeona Submits BLA for RDEB Treatmenthttps://practicaldermatology.com/news/abeona-submits-bla-for-rdeb-treatment/2462026/Abeona Therapeutics Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). <
- Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-initiates-clinical-proof-of-concept-study-of-ep262/2462020/The first patient has been dosed in Escient Pharmaceuticals CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262, a first-in-class oral MRGPRX2 antagonist for chronic inducible urticaria. By blocking activation of MRGPRX2 and degranulation of mast cells,
- Colloidal Oatmeal Cream Soothes AD in Black Childrenhttps://practicaldermatology.com/news/colloidal-oatmeal-cream-soothes-ad-in-black-children/2462018/Oatmeal cream may help ease atopic dermatitis in Black children, according to research presented at the Science of Skincare Summit in Austin, Texas. Black children are 1.7 times more likely to dev
- Exploring the Link Between Sex Hormones and Melanoma Riskhttps://practicaldermatology.com/news/exploring-the-link-between-sex-hormones-and-melanoma-risk/2462016/Researchers out of the University of Tennessee Health Science Center are beginning a study to determine whether sex hormones affect the risk of melanoma The team received a $423,500 grant from the National Institute of Environmental Health Sciences, part of the National Institutes of He
- MTX vs. CsA in AD: Which Is Best for Kids?https://practicaldermatology.com/news/mtx-vs-csa-in-ad-which-is-best-for-kids/2462008/Methotrexate bested cyclosporine in children with severe atopic dermatitis, a new study shows. While new systemic therapies for AD are being introduced, researchers want to est
- Encouraging Preclinical Results Seen for Scinai’s NanoAbs in Plaque Psoriasishttps://practicaldermatology.com/news/encouraging-preclinical-results-seen-for-scinais-nanoabs-in-plaque-psoriasis/2462006/Scinai Immunotherapeutics Ltd.’s anti‑interleukin 17 (IL‑17) NanoAbs downregulated key molecular markers that are overexpressed in plaque psoriasis, according to preclinical data relased by Scinai. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-
- One to Watch: Nektar Therapeutics' Rezpegaldesleukin Shows Promise in Phase 1b AD Studyhttps://practicaldermatology.com/news/one-to-watch-nektar-therapeutics-rezpegaldesleukin-shows-promise-in-phase-1b-ad-study/2462000/Nektar Therapeutics’ rezpegaldesleukin met several clinical efficacy endpoints with statistically significance, including Body Surface Area (BSA), Dermatology Life (DLQI), and Patient-Oriented Eczema Measure (POEM) in addition to reported efficacy for Eczema Area and Severity